Tg Therapeutics (TGTX) Cash from Investing Activities (2011 - 2026)

Tg Therapeutics' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$9.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 23.74% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 457.77% YoY), while the FY2025 annual figure was $13.8 million, up 1431.95% from the prior year.
• Cash from Investing Activities was -$9.9 million for Q1 2026 at Tg Therapeutics, up from -$15.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $46.4 million in Q3 2025 to a low of -$44.8 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$4.0 million across 5 years, with a median of -$6.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 8396.3% in 2022, then surged 596.71% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $16.3 million in 2022, then slumped by 375.09% to -$44.8 million in 2023, then jumped by 135.28% to $15.8 million in 2024, then tumbled by 199.05% to -$15.6 million in 2025, then surged by 36.92% to -$9.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$9.9 million (Q1 2026), -$15.6 million (Q4 2025), and $46.4 million (Q3 2025), per Business Quant data.